


## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently Amended): A 3-hydroxypyridin-4-one compound of formula I:



wherein:

$R^1$  is X with the proviso that  $R^2$  is Y;

or

$R^1$  is T with the proviso that  $R^2$  is W;

or

~~$R^1$  is X with the proviso that  $R^2$  and  $R^5$  when taken together, form a heterocyclic ring selected from piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl, wherein the group piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl is either unsubstituted or substituted with one to three  $C_1$  to  $C_6$  alkyl groups;~~

X is  $C_3$ - $C_6$  cycloalkyl;

Y is selected from the group consisting of  $C_3$ - $C_6$  cycloalkyl,  $C_1$  to  $C_6$  alkyl and  $C_1$  to  $C_6$  alkyl monosubstituted with a  $C_3$ - $C_6$  cycloalkyl;

T is  $C_1$  to  $C_6$  alkyl;

W is C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

R<sup>3</sup> is selected from the group consisting of hydrogen and C<sub>1</sub> to C<sub>6</sub> alkyl;

R<sup>4</sup> is selected from the group consisting of hydrogen and C<sub>1</sub> to C<sub>6</sub> alkyl;

R<sup>5</sup> is selected from the group consisting of hydrogen and C<sub>1</sub> to C<sub>6</sub> alkyl;

and/or a pharmaceutically acceptable salt thereof.

2. (Original): A compound according to claim 1 wherein R<sup>1</sup> is X with the proviso that R<sup>2</sup> is Y.
3. (Original): A compound of claim 2 wherein X is C<sub>3</sub>-C<sub>6</sub> cycloalkyl, Y is C<sub>1</sub> to C<sub>6</sub> alkyl and R<sup>5</sup> is hydrogen or methyl.
4. (Currently Amended): A compound of claim 3 wherein X is cyclopropyl, Y is methyl, R<sup>3</sup> is hydrogen, R<sup>4</sup> is methyl and R<sup>5</sup> is hydrogen, and wherein said compound is 1-cyclopropyl-3-hydroxy-6-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid methylamide.
5. (Original): A pharmaceutical composition comprising 1-cyclopropyl-3-hydroxy-6-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid methylamide and a pharmaceutically acceptable carrier.
6. (Currently Amended): The pharmaceutical composition of claim 5, which is adopted for oral administration.
7. (Original): A compound of claim 2 wherein X is C<sub>3</sub>-C<sub>6</sub> cycloalkyl, Y is C<sub>3</sub>-C<sub>6</sub> cycloalkyl and R<sup>5</sup> is hydrogen.
8. (Currently Amended): A compound of claim 7 wherein X is cyclopropyl, Y is cyclopropyl, R<sup>3</sup> is hydrogen, R<sup>4</sup> is methyl, and wherein said compound is N,1-dicyclopropyl-3-hydroxy-6-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide.
9. (Currently Amended): A compound of claim 3 wherein X is cyclopropyl, Y is methyl, R<sup>3</sup> is hydrogen, R<sup>4</sup> is methyl and R<sup>5</sup> is methyl, and wherein said

compound is 1-cyclopropyl-3-hydroxy-*N,N*,6-trimethyl-4-oxo-1,4-dihydropyridine-2-carboxamide.

10. (Original): A compound according to claim 1 wherein  $R^1$  is T with the proviso that  $R^2$  is W.
11. (Original): A compound of claim 10 wherein T is  $C_1$ - $C_6$  alkyl and W is  $C_3$ - $C_6$  cycloalkyl.
12. (Currently Amended): A compound of claim 11 wherein T is methyl, W is cyclopropyl,  $R^3$  is hydrogen,  $R^4$  is methyl and  $R^5$  is hydrogen, and wherein said compound is 3-hydroxy-1,6-dimethyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid cyclopropylamide.
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).
16. (Original): A pharmaceutical composition comprising a compound according to claim 1 and a physiologically acceptable carrier.
17. (Original): A pharmaceutical composition according to claim 16, which is adopted for oral administration.
18. (Currently Amended): ~~Use of a compound according to claim 1 in the manufacture of medicament in the treatment of a~~ A method of treating at least one medical condition related to a toxic concentration of iron comprising administering to an animal suffering from said condition a therapeutically effective amount of the compound of claim 4, wherein said at least one medical condition is selected from the group consisting of thalassaemia, sickle cell disease and haemochromatosis.